by Peter Ciszewski | Aug 10, 2018
The Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ patisiran (Onpattro) infusion for the treatment of polyneurotherapy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first approved treatment for...
by Peter Ciszewski | Aug 10, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Richard West, Founder and CEO of Baebies, a newborn testing diagnostic company. In this video, Mr West discusses the company’s two main platforms. SEEKER is a...
by Peter Ciszewski | Aug 9, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Brian Schwartz, Chief Medical Officer of ArQule, discusses his company and it’s focus on disease management. ArQule is engaged in the research and...
by Peter Ciszewski | Aug 8, 2018
Heather A. Lau, MD, Director, Lysosomal Storage Disease Program at NYU Langone in New York City discusses the correlation between non-immune Hydrops fetalis (NIHF) and MPS VII. Hydrops fetalis is a serious condition in which abnormal amounts of fluid build up...
by Peter Ciszewski | Aug 7, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Barry Greene, President of Alnylam, provides RNA interference (RNAi) and the first ever new class of innovative medicines to potentially enter the market this...
